The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Adria Myers has no relevant financial relationships to disclose. Holly Chitwood has participated in oncology nurse education advisory boards with Gilead Sciences, Astra Zeneca, and in biomarker database peer review for the Oncology Nursing Society.
Learning Objectives:
Define circulating tumor DNA (ctDNA) and appraise evolving technology
Describe current ctDNA application with solid tumors and emerging indications in practice with an overview of commercially available assays
Discuss the advanced practice provider's role in ctDNA utilization
Identify emerging clinical trial data and evolving recommendations for ctDNA utilization
Speaker(s):
Holly
R. Chitwood,
Assistant Professor,
University of Kentucky Markey Cancer Center
Adria
Myers,
Advanced Practice Provider II,
University of Kentucky Markey Cancer Center
You must be logged in and own this session in order to
post comments.